Vericel/$VCEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vericel
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
- Ticker
- $VCEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 398
- Headquarters
- Burlington, United States
- Website
- www.vcel.com
Vericel Metrics
BasicAdvanced
$2.1B
86.60
$0.47
1.07
-
Price and volume
Market cap
$2.1B
Beta
1.07
52-week high
$49.32
52-week low
$28.95
Average daily volume
528K
Financial strength
Current ratio
5.039
Quick ratio
4.534
Long term debt to equity
0.213
Total debt to equity
0.252
Interest coverage (TTM)
28.49%
Profitability
EBITDA (TTM)
31.154
Gross margin (TTM)
74.56%
Net profit margin (TTM)
7.91%
Operating margin (TTM)
5.95%
Effective tax rate (TTM)
3.42%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
2.43%
Return on equity (TTM)
7.16%
Valuation
Price to earnings (TTM)
86.596
Price to revenue (TTM)
6.728
Price to book
5.62
Price to tangible book (TTM)
5.7
Price to free cash flow (TTM)
33.42
Free cash flow yield (TTM)
2.99%
Free cash flow per share (TTM)
1.215
Growth
Revenue change (TTM)
22.95%
Earnings per share change (TTM)
251.23%
3-year revenue growth (CAGR)
19.79%
10-year revenue growth (CAGR)
19.03%
3-year earnings per share growth (CAGR)
19.03%
10-year earnings per share growth (CAGR)
-7.28%
What the Analysts think about Vericel
Analyst ratings (Buy, Hold, Sell) for Vericel stock.
Analyst projections of the future price of Vericel stock.
Bulls say / Bears say
Vericel is showing strong operating momentum: second-quarter revenue rose 22% to $77.5 million, MACI revenue rose 23%, and management raised 2026 revenue guidance to $330–340 million. It also generated $14.3 million of free cash flow and held about $227 million in cash and investments with no debt. (Vericel, SEC filing mirror)
MACI has room to expand beyond its established US knee market. Vericel has received FDA approval to manufacture MACI at its new facility and submitted a UK marketing application, creating a possible 2027 launch while also building a longer-term option in ankle cartilage repair. (Vericel, StockAnalysis)
Burn care is becoming a useful second growth engine. Epicel revenue rose 21% in the second quarter, NexoBrid reached a record quarter, and a BARDA contract worth up to $197 million could support procurement and development over ten years, although only the base period is committed. (Vericel, Vericel)
The business remains heavily dependent on MACI: it generated $65.5 million of $77.5 million in second-quarter revenue. Any slowdown in surgeon adoption, procedure volumes, pricing or reimbursement would therefore have an outsized effect on group growth. (Vericel, SEC filing mirror)
Manufacturing and supply-chain execution remain material risks during expansion. Vericel is still moving MACI production to its Burlington facility, while NexoBrid is manufactured primarily by MediWound in Israel and uses bromelain sourced from Taiwan, leaving potential disruption points outside Vericel’s direct control. (Vericel, SEC filing mirror)
Several headline growth opportunities are still distant or unapproved. The UK launch depends on regulatory review, while the ankle programme involves roughly three years of enrolment, two years of follow-up and potential approval only in the early 2030s, so they may add little to near-term results. (StockAnalysis, Vericel)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Vericel Financial Performance
Revenues and expenses
Vericel Earnings Performance
Company profitability
Upcoming events
No upcoming events
Vericel News
AllArticlesVideos
Funds containing Vericel
AllUSDEURGBP
Fund name | Fund size | $VCEL weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.18% |
iShares Ageing Population€AGED | €822M | 0.18% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.14% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.